CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs
| Autor: | Caroline L, Ng, Giulia, Siciliano, Marcus C S, Lee, Mariana J, de Almeida, Victoria C, Corey, Selina E, Bopp, Lucia, Bertuccini, Sergio, Wittlin, Rachel G, Kasdin, Amélie, Le Bihan, Martine, Clozel, Elizabeth A, Winzeler, Pietro, Alano, David A, Fidock |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Acrylamides
Plasmodium falciparum Drug Resistance Drug Synergism DNA Protozoan Polymorphism Single Nucleotide Artemisinins Piperazines Article Antimalarials parasitic diseases Humans Point Mutation ATP-Binding Cassette Transporters Clustered Regularly Interspaced Short Palindromic Repeats Malaria Falciparum Multidrug Resistance-Associated Proteins |
| Zdroj: | Molecular microbiology. 101(3) |
| ISSN: | 1365-2958 |
| Popis: | Emerging resistance to first-line antimalarial combination therapies threatens malaria treatment and the global elimination campaign. Improved therapeutic strategies are required to protect existing drugs and enhance treatment efficacy. We report that the piperazine-containing compound ACT-451840 exhibits single-digit nanomolar inhibition of the Plasmodium falciparum asexual blood stages and transmissible gametocyte forms. Genome sequence analyses of in vitro-derived ACT-451840-resistant parasites revealed single nucleotide polymorphisms in pfmdr1, which encodes a digestive vacuole membrane-bound ATP-binding cassette transporter known to alter P. falciparum susceptibility to multiple first-line antimalarials. CRISPR-Cas9 based gene editing confirmed that PfMDR1 point mutations mediated ACT-451840 resistance. Resistant parasites demonstrated increased susceptibility to the clinical drugs lumefantrine, mefloquine, quinine and amodiaquine. Stage V gametocytes harboring Cas9-introduced pfmdr1 mutations also acquired ACT-451840 resistance. These findings reveal that PfMDR1 mutations can impart resistance to compounds active against asexual blood stages and mature gametocytes. Exploiting PfMDR1 resistance mechanisms provides new opportunities for developing disease-relieving and transmission-blocking antimalarials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text